Atossa Therapeutics Q1 2026 Earnings Narrowed Loss Beats Estimates as Clinical Pipeline Advances NMFCZ Q1 2026 Earnings Missed Estimates by Narrow Margin as EPS Comes in at 032 CANF Q4 2023 Earnings EPS Surges Past Estimates as Clinical Progress Continues TTD Q1 2026 Earnings EPS Misses Estimates But Stock Climbs on Strong Operational Momentum LOW Q1 2026 Earnings EPS Beats Estimates by 092 Stock Dips Slightly UHT Q1 2026 Earnings EPS Beats in Absence of Consensus Shares Edge Higher